Sponsors Continue to Push for More Flexibility in DMD Drug Development

Clinical Trials Advisor
A A
Drugmakers and patient groups are pressing the FDA for more leeway on approaches to developing drugs for Duchenne Muscular Dystrophy, saying a June draft guidance doesn’t go far enough.

To View This Article:

Login

Subscribe To Clinical Trials Advisor